EQS-News
Grünenthal GmbH: Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress - Seite 3
In November 2022, Grünenthal acquired Nebido, a leading brand for testosterone replacement therapy, from Bayer for ~€495 million. The brand immediately contributed to Grünenthal's revenue and profit as of November 2022. Another milestone in Grünenthal's M&A strategy was the announcement to enter into a joint venture agreement with Kyowa Kirin International. The joint venture includes 13 established brands with revenues primarily from pain management products. Grünenthal will own a 51 percent majority share in the new company. Grünenthal intends to acquire the remaining 49 percent share at the beginning of 2026. Since 2017, Grünenthal has closed successful acquisitions with a total expected deal value of more than €2.0 billion, including Zomig, Nexium, Vimovo, Crestor, and Nebido.
In addition to serving patients suffering from pain, Grünenthal aims to positively impact its employees, partners, and society – while reducing the environmental footprint of its business activities. Grünenthal is a recognised leader in Environment, Social and Governance (ESG) in its industry. In July 2022, an ESG rating agency placed Grünenthal in the top 3 percent of the pharmaceutical sub-industry, acknowledging the strong management of its ESG risks.
Driving a high-performance culture is key to Grünenthal's success. Following excellent employee engagement scores during the 2022 survey, Grünenthal has 24 entities worldwide certified as a Great Place to Work. In 2022, Grünenthal also made further progress in attracting and developing talents by launching a dedicated Diversity & Engagement strategy.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.